Cybersecurity and Data Integrity Considerations for Connected Diagnostics Cybersecurity and Data Integrity Considerations for Connected Diagnostics In the evolving landscape of healthcare, connected diagnostics, including in vitro diagnostics (IVDs) and software as a medical device (SaMD), introduce unique regulatory challenges. Regulatory Affairs (RA) professionals must navigate complex guidelines, particularly regarding cybersecurity and data integrity. This article provides a comprehensive overview, defining the regulatory context, detailing key regulations and guidelines, elucidating documentation expectations, and outlining common deficiencies encountered in the review process. Additionally, special attention will be given to decision-making moments relevant to both manufacturers and regulatory bodies. Context The global…

Interfacing Drug, Device and Software Regulatory Teams in One Program Interfacing Drug, Device and Software Regulatory Teams in One Program In the evolving landscape of healthcare, the integration of drug, device, and software regulatory teams has become paramount, especially within the framework of pharmacovig. This article serves as a comprehensive regulatory explainer manual focusing on the intersections of Companion Diagnostics, In Vitro Diagnostics (IVDs), Software as a Medical Device (SaMD), and the broader implications for regulatory affairs within the special product categories and advanced therapies. It highlights critical regulations, guidelines, and agency expectations within the US, EU, and UK, ensuring…

Real-World Data and Evidence for Diagnostics and SaMD Performance Real-World Data and Evidence for Diagnostics and SaMD Performance In an ever-evolving landscape of medical technologies, regulatory affairs professionals must navigate complex frameworks to ensure compliance with the requirements for diagnostics, Software as a Medical Device (SaMD), and other advanced products. This article delves into the regulations and guidelines concerning the use of real-world data (RWD) in the context of diagnostics and SaMD, particularly focusing on pharmacovigilance and special product regulatory pathways. Context Regulatory Affairs (RA) plays a crucial role in ensuring that newly developed diagnostics and SaMD align with regulatory…

Governance and Responsibility Splits in Pharma–Diagnostic Partnerships Governance and Responsibility Splits in Pharma–Diagnostic Partnerships Context In the rapidly evolving landscape of pharmaceuticals and diagnostics, the integration of companion diagnostics, in vitro diagnostics (IVDs), and Software as a Medical Device (SaMD) creates unique regulatory challenges. These challenges are borne from the necessity to clearly delineate responsibilities and regulatory pathways when developing combination products that often straddle both the pharmaceutical and diagnostic realms. This article serves as a comprehensive guide for regulatory affairs professionals navigating these complexities, with a specific focus on the roles of key stakeholders and the intersection of regulations…

Templates for Companion Diagnostic Regulatory Strategy Briefing Packs Templates for Companion Diagnostic Regulatory Strategy Briefing Packs In the complex landscape of pharmaceutical and biotechnology development, navigating the regulatory environment for Companion Diagnostics (CDx) and In Vitro Diagnostics (IVDs) requires a comprehensive understanding of the associated regulatory frameworks. This article is intended for Regulatory Affairs (RA), Chemistry, Manufacturing and Controls (CMC), and Labelling teams in US and EU pharmaceutical companies. It provides a structured regulatory explainer manual to guide professionals through the intricacies of regulatory strategies for CDx, including templates for regulatory strategy briefing packs. Regulatory Affairs Context Companion Diagnostics are…

Managing Change Control for IVDs and SaMD That Support Approved Drugs Managing Change Control for IVDs and SaMD That Support Approved Drugs In the realm of pharmaceutical regulation, In Vitro Diagnostics (IVDs) and Software as a Medical Device (SaMD) that support approved drugs represent a unique and increasingly critical intersection. Regulatory Affairs (RA) teams must navigate a complex landscape of guidelines, regulations, and standards that vary by jurisdiction, particularly in the US, UK, and EU. This article serves as a comprehensive manual on managing change control for these products within the context of pharmacovigilance systems and special product regulatory pathways….

Global Harmonisation Challenges for Diagnostic Regulation and Distribution Global Harmonisation Challenges for Diagnostic Regulation and Distribution Context The pharmaceutical and biotechnology landscape is evolving rapidly, particularly in the domains of diagnostics and advanced therapies. Regulatory Affairs (RA) professionals must navigate complex frameworks to ensure compliance with various regulations across jurisdictions, notably the United States, European Union, and the United Kingdom. This article explores the intricacies of regulatory compliance consulting, specifically regarding companion diagnostics, in vitro diagnostics (IVDs), and Software as a Medical Device (SaMD) within the RA/device interface. Legal/Regulatory Basis The regulatory framework governing diagnostics and advanced therapies is vast…

Digital Pathology, AI-Driven Algorithms and Regulatory Expectations Digital Pathology, AI-Driven Algorithms and Regulatory Expectations The landscape of regulatory affairs is rapidly evolving, particularly with the advent of advanced therapies, including digital pathology and AI-driven algorithms. This regulatory explainer manual aims to provide comprehensive insights into the regulatory framework governing these special product categories. Regulatory professionals in the pharmaceutical and biotechnology sectors need to understand the implications of these products on regulatory compliance and the overall regulatory pathway they follow. Regulatory Context Digital pathology involves the use of digital imaging technologies to create high-resolution images of pathology slides, facilitating the diagnosis…

Engaging Early with Regulators on Novel Diagnostic Concepts and Tools Engaging Early with Regulators on Novel Diagnostic Concepts and Tools Context In the rapidly evolving landscape of diagnostics, particularly with the rise of Companion Diagnostics (CDx), In Vitro Diagnostics (IVDs), and Software as a Medical Device (SaMD), engaging with regulators at an early stage is critical. Regulatory Affairs (RA) professionals play an integral role in navigating the complex frameworks governing these products. This article aims to elucidate the relevant regulations and guidelines, optimal documentation practices, and common pitfalls to avoid during the regulatory process in the US, UK, and EU….

Future Trends: Personalised Medicine, Multi-Analyte Panels and AI Diagnostics Future Trends: Personalised Medicine, Multi-Analyte Panels and AI Diagnostics Context In the evolving landscape of healthcare, especially within the domains of oncology, infectious diseases, and personalized medicine, the roles of companion diagnostics, in vitro diagnostics (IVDs), and software as a medical device (SaMD) are becoming increasingly prominent. Regulatory Affairs professionals must stay abreast of the relevant guidelines that govern these special product categories. In this article, we will explore these trends, focusing on regulatory expectations in the US, EU, and UK, and offering insights into the necessary documentation, review and approval…